What is Erste Group Bank's Forecast for NVO FY2026 Earnings?

Key Points

• Erste Group Bank lowered Novo Nordisk’s FY2026 EPS forecast to $3.29 from $3.43, below the $3.53 analyst consensus. It projects FY2027 EPS of $3.25.
• Novo Nordisk recently reported quarterly EPS of $0.94 on revenue of $11.98 billion, with a 35.36% net margin and 58.61% return on equity.
• Analyst sentiment is broadly cautious: the stock carries a consensus “Hold” rating and an average price target of $59.44, while its shares recently opened at $38.60.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Equities research analysts at Erste Group Bank lowered their FY2026 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.29 per share for the year, down from their prior estimate of $3.43. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.53 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S's FY2027 earnings at $3.25 EPS.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.

A number of other brokerages also recently commented on NVO. Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Weiss Ratings downgraded Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday. BMO Capital Markets set a $40.00 target price on Novo Nordisk A/S and gave the company a "market perform" rating in a research report on Monday. Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Finally, Cfra lowered shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating and set a $38.00 price target for the company. in a research report on Tuesday, September 22nd. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $59.44.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $38.60 on Tuesday. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company's 50 day moving average price is $43.25 and its two-hundred day moving average price is $43.89. The stock has a market cap of $172.36 billion, a P/E ratio of 9.44, a P/E/G ratio of 1.27 and a beta of 0.76. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NVO. CoreCap Advisors LLC lifted its stake in Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company's stock valued at $256,000 after buying an additional 242 shares in the last quarter. Carson Advisory Inc. increased its stake in Novo Nordisk A/S by 2.2% during the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company's stock worth $453,000 after buying an additional 268 shares in the last quarter. Byrne Asset Management LLC increased its stake in Novo Nordisk A/S by 9.7% during the 3rd quarter. Byrne Asset Management LLC now owns 3,055 shares of the company's stock worth $114,000 after buying an additional 270 shares in the last quarter. Bradley Foster & Sargent Inc. CT increased its stake in Novo Nordisk A/S by 0.6% during the 1st quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company's stock worth $1,726,000 after buying an additional 272 shares in the last quarter. Finally, Arlington Partners LLC lifted its position in shares of Novo Nordisk A/S by 4.4% in the second quarter. Arlington Partners LLC now owns 6,777 shares of the company's stock valued at $325,000 after acquiring an additional 283 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date was Monday, August 17th. This is a decrease from Novo Nordisk A/S's previous dividend of $1.2751. Novo Nordisk A/S's dividend payout ratio is currently 20.05%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.